MedPath

efficacy and safety of oral pioglitazone in treatment of lichen planopilaris

Phase 3
Recruiting
Conditions
ichen planopilaris.
Lichen planopilaris
L66.1
Registration Number
IRCT20230415057912N1
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
30
Inclusion Criteria

a disease that is resistant to treatment. It means that the treatment has been ineffective for at least 6 months.
Newly diagnosed patients who have not yet received treatment.
Patients who have been treated before and whose disease is still active.
Patients who, for any reason, have discontinued any previous medication 1 month before entering the study and have not used any other medication at the time of the study.
Patients between 18 and 50 years old

Exclusion Criteria

Pregnancy or breastfeeding
wbc<3000
platelet<100000
hemoglobin<9
Liver enzymes that are too normal for reference and active liver disease
Positive tests for viral hepatitis
Heart failure
Type 1 diabetes
Allergy to pioglitazone and methotrexate
Bladder cancer
Tissue edema

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ichen Planopilaris Activity Index. Timepoint: Months 0, 2, 4, and 6 after starting the drug. Method of measurement: Handyscope dermatoskope (FotoFinder System GmbH, Bad Brinbach, Germany.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath